Abbott/Kos’ Integrated Sales Force Expected To Accelerate Niaspan Growth
This article was originally published in The Pink Sheet Daily
Executive Summary
Abbott says there will be “synergistic” effects from folding Niaspan into its cholesterol portfolio that will improve sales over those seen when Kos was the sole marketer.
You may also be interested in...
New Niaspan Tablets Gain FDA Approval
Coated tablet version of Abbott’s cholesterol therapy reduces flushing, firm claims.
New Niaspan Tablets Gain FDA Approval
Coated tablet version of Abbott’s cholesterol therapy reduces flushing, firm claims.
Abbott Targets Simcor Filing For First Half 2007
Addition of Kos nearly doubles Abbott's 2007 dyslipidemia franchise.